

BC PharmaCare Drug Information

The drug below is being considered for possible coverage under the B.C. PharmaCare program. PharmaCare is a government-funded drug plan that helps British Columbians with the cost of eligible prescription drugs and specific medical supplies. For more information on PharmaCare, visit [Ministry of Health - PharmaCare](#).

PharmaCare reviews each drug for treating a specific illness or medical condition (known as an “indication”). If a decision is made to cover the drug, it will be only for that illness or condition.

In some cases, PharmaCare may cover a drug only for people who have the illness or condition and have not responded to other drugs used to treat that illness or condition.

For more information on PharmaCare’s drug coverage review process, see the last page of this information sheet.

Information about the drug	
Generic name (scientific name)	travoprost ophthalmic solution
Brand name	Izba™
Manufacturer	Novartis Pharmaceuticals Canada Inc.
Indication	Open-angle glaucoma and ocular hypertension
Has the drug been reviewed by the Common Drug Review (CDR)? (see the note below this table.)	Yes For more information about the CDR’s review of travoprost ophthalmic solution (Izba™), you can Search the CDR Reports .
Public input start date	Wednesday June 28, 2017
Public input closing date	Wednesday July 26, 2017 AT MIDNIGHT
How is the drug taken?	Izba is administered by drops into the affected eye.
How often is the drug is taken?	Izba is administered one drop daily in each affected eye.

Information about the drug	
General drug and/or drug study information	<p>Izba is used to treat high pressure in fluid in the eye (ocular hypertension). This pressure can lead to an illness called glaucoma.</p> <p>The eyeballs contain a clear, watery liquid which feeds the inside of the eye. Liquid is always emptying out of the eye and more liquid is always being produced. If the eye fills up faster than it empties, the pressure inside the eye builds up. If it gets too high, it can damage sight.</p> <p>Izba is a 0.003% solution of travoprost preserved with Polyquaternium-1 (PQ). It is one of a group of medicines for glaucoma called prostaglandins. It works by increasing the outflow of liquid, which lowers the pressure in the eye. It may be used on its own or with other glaucoma eye drops, which also reduce pressure.</p> <p>Studies looked at the following to determine if Izba is as safe and effective for the treatment of glaucoma and ocular hypertension as travoprost 0.004% optical solution, preserved with benzalkonium chloride (BAC):</p> <ul style="list-style-type: none"> • Mean intraocular pressure (fluid pressure inside the eye) measured in millimetres of mercury (mmHg) • Mean change in intraocular pressure from baseline • Percentage of patients who achieved a target intraocular pressure of less than 18 mmHg at each visit and • Percentage of patients who achieved lowering of intraocular pressure of at least 30% from baseline at each visit • Bad reactions • Serious bad reactions • Patients leaving the trial due to bad reactions • Bad reactions of special interest (best corrected visual acuity [BCVA], ocular signs)
Other considerations	None

Note:

The Common Drug Review (CDR) is a national organization that reviews drugs on behalf of Canadian public sector plans when manufacturers want to have the jurisdictions provide coverage for the drugs. For detailed information on B.C. PharmaCare’s drug review process, including the role of the CDR in that process, see [The Drug Review Process in B.C. - Overview](#).

Cost of the drug under review compared to other drugs used to treat the same indication			
generic name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Usual Dose	Daily Cost of Therapy (\$)
travoprost 0.003% (Izba™) <i>preserved with PQ</i>	Under Review	One drop daily in each affected eye	0.25 ^a
Prostaglandin analogues			
travoprost 0.004% (Travatan® Z and generics) <i>preserved with SoFzia®</i>	Regular Benefit	One drop daily in each affected eye	0.23 ^b
latanoprost 0.005% (Xalatan® and generics)	Regular Benefit	One drop daily in each affected eye	0.24 ^b
bimatoprost 0.01% (Lumigan RC®)	Regular Benefit	One drop daily in each affected eye	0.72 ^b
bimatoprost 0.03% (Vistitan™)	Non-Benefit	One drop daily in each affected eye	0.53 ^c

Notes:

It was assumed that all drop sizes were the same across treatments (35 drops/mL).

It was assumed that both eyes were treated.

A - Manufacturer submitted price.

b - Cost based on PharmaNet data

c - Cost based CADTH CDR Pharmacoeconomic Review Report TRAVOPROST 0.003% (IZBA)

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, visit: [The Drug Review Process in B.C. - Overview](#).

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.